mood disorders
Gabather approaching initial target engagement study results
Gabather's target engagement study with the lead candidate GT-002, a treatment for neuropsychiatric disorders, is expected to produce its...
Intervju
Gabather’s lead candidate moves forward in the clinic
Swedish biotech Gabather has received the approval from...
Intervju
BioStock Studio: Gabather gives clinical trial update
Gabather’s top candidate GT-002 for treating psychiatric or...
BioStock TV
Intervju
Gabather – focus on CNS diseases
Diseases of the central nervous system (CNS) and...
